Loading...
Loading...
CGTX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 14.5M |
| Operating I/L | -14.5M |
| Other Income/Expense | 4.5M |
| Interest Income | 0.0M |
| Pretax | -9.9M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -9.9M |
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of small molecule therapeutics for age-related degenerative diseases and central nervous system disorders. Their lead product candidate, CT1812, is in Phase II clinical trials for mild-to-moderate Alzheimer's disease and dementia with Lewy bodies, with potential applications for dry age-related macular degeneration. Additionally, the company is developing CT2168 for synucleinopathies and CT2074 for dry AMD. Their revenue model is based on the successful development and commercialization of these innovative therapeutics targeting unmet medical needs in the aging population.
